Agios Pharmaceuticals Announces Board and Compensation Changes
Ticker: AGIO · Form: 8-K · Filed: Feb 13, 2025 · CIK: 1439222
| Field | Detail |
|---|---|
| Company | Agios Pharmaceuticals, Inc. (AGIO) |
| Form Type | 8-K |
| Filed Date | Feb 13, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, executive-compensation, board-changes
TL;DR
Agios Pharma shakes up board & exec pay. Effective Feb 10.
AI Summary
On February 10, 2025, Agios Pharmaceuticals, Inc. announced changes in its board of directors and executive compensation arrangements. The company filed an 8-K report detailing these updates, which are effective as of the reporting date.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — The filing reports routine corporate governance changes and does not indicate any significant financial distress or operational disruption.
Key Players & Entities
- Agios Pharmaceuticals, Inc. (company) — Registrant
- February 10, 2025 (date) — Effective date of reported changes
- Delaware (jurisdiction) — State of incorporation
- 88 Sidney Street, Cambridge, MA 02139 (address) — Principal Executive Offices
FAQ
What specific changes were made to the board of directors?
The filing indicates an 'Election of Directors' and 'Departure of Directors or Certain Officers,' but the specific names and details of these changes are not provided in the excerpt.
What are the details of the compensatory arrangements for certain officers?
The filing mentions 'Compensatory Arrangements of Certain Officers,' but the specific details of these arrangements are not included in the provided text.
What is the primary business of Agios Pharmaceuticals, Inc.?
Agios Pharmaceuticals, Inc. is in the 'PHARMACEUTICAL PREPARATIONS' industry, SIC code 2834.
When was the company incorporated and what is its fiscal year end?
The company was incorporated in Delaware and its fiscal year ends on December 31.
What is the SEC file number for Agios Pharmaceuticals, Inc.?
The SEC file number for Agios Pharmaceuticals, Inc. is 001-36014.
Filing Stats: 447 words · 2 min read · ~1 pages · Grade level 11.2 · Accepted 2025-02-13 06:01:47
Key Financial Figures
- $0.001 — ich registered Common Stock, Par Value $0.001 per share AGIO Nasdaq Global Select
Filing Documents
- d927492d8k.htm (8-K) — 21KB
- 0001193125-25-025524.txt ( ) — 136KB
- agio-20250210.xsd (EX-101.SCH) — 3KB
- agio-20250210_lab.xml (EX-101.LAB) — 17KB
- agio-20250210_pre.xml (EX-101.PRE) — 11KB
- d927492d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AGIOS PHARMACEUTICALS, INC. Date: February 13, 2025 By: /s/ Brian Goff Brian Goff Chief Executive Officer